Arca biopharma, inc. (ABIO)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Costs and expenses:
Research and development

1,833

4,239

14,076

12,348

7,063

5,625

2,928

1,092

2,315

General and administrative

3,981

3,879

4,636

4,265

4,392

4,068

4,012

-

-

General and administrative

-

-

-

-

-

-

-

3,227

5,046

Total costs and expenses

5,814

8,118

18,712

16,613

11,455

9,693

-

4,319

7,361

Total costs and expenses

-

-

-

-

-

-

6,940

-

-

Loss from operations

-5,814

-8,118

-18,712

-16,613

-11,455

-9,693

-6,940

-4,319

-7,361

Gain on assignment of patent rights

-

-

-

-

-

-

-

-

2,000

Interest and other income

172

162

167

169

14

7

5

2

2

Interest expense

7

8

6

-

4

3

4

-

-

Loss before income taxes

-5,649

-7,964

-18,551

-16,444

-

-

-

-

-

Interest and other expense

-

-

-

-

-

-

-

3

5

Loss before income taxes

-

-

-

-

-

-

-

-4,320

-5,364

Income tax benefit

-167

-31

-61

0

-

-

-

0

-

Net loss

-5,482

-7,933

-18,490

-16,444

-11,445

-9,689

-6,939

-4,320

-5,364

Change in unrealized loss on marketable securities

-

2

17

-19

-

-

-

-

-

Comprehensive loss

-5,482

-7,931

-18,473

-16,463

-11,445

-

-

-

-

Net loss per share:
Less: Deemed preferred stock dividend

-

-

-

-

-

-

2,026

-

-

Net loss available to common stockholders

-

-

-

-

-

-

-8,965

-4,320

-5,364

Basic and diluted

-4.15

-10.31

-1.77

-1.81

-1.82

-3.31

-1.04

-1.94

-3.21

Weighted average shares outstanding:
Basic and diluted

1,321

769

10,431

9,067

6,289

2,928

8,629

2,223

1,673